mesothelioma

Researchers, FDA Evaluating Experimental Gene Therapy Procedures for Mesothelioma Treatment

According to the BBC (November 2012), geneticists, scientists and the entire medical profession are applauding the European Commission for bringing ‘a new era to medicine in the Western world’ by approving Glycera, a Dutch gene therapy medicine for treating a rare, inherited disorder known as LPLD. While gene therapy has been gaining momentum for years since French scientists first used it in 2000 to treat a rare immune disorder called SCID, Glycera’s approval may be the breakthrough needed to move gene therapy to sufferers of other rare diseases such as mesothelioma.